Orgenesis Inc. (ORGS), a leading cell and gene therapy enabling company providing centralized CDMO manufacturing and development services, as well as localized point-of-care development and processing centers through its subsidiary Orgenesis Maryland, Inc., today announced the addition of the University of California, Davis (UC Davis) to its Point of Care (“POCare”) Network. Under the collaboration agreement, UC Davis Health will utilize Orgenesis’ POCare platform to develop, commercialize and supply cell and gene products and therapies.

Orgenesis plans to combine ranpirnase with its co-developed Bioxome™ technology for enhanced payload delivery directly to cells. TamirBio is a clinical stage anti-viral therapeutics company engaged in the discovery and development of a new class of prophylactic and therapeutic drugs for the treatment of viruses and other pathological conditions.

The Company has been working aggressively the last few months to repurpose its cell-based vaccine platform targeting solid tumors for use against viral diseases. The cell-based vaccine platform utilizes irradiated permissive cells (human or non-human, infected with a high titer virus or transfected with viral antigens), which then activate endogenous dendritic cells. CD4+ cells activate humoral immune response via B cells, which generate neutralizing antibodies, while CD8+ cell mount cytotoxic immune response against virus-infected cells.

The Medicine Maker has published its Power List annually since 2015. For 2020, its sixth list was shortened from 100 to 60 entrants, with three top 20 lists celebrating the most influential leaders in what the publication considers the most important fields in medicine making in 2020 -  biopharmaceuticals, advanced therapies and small molecules.

D.C. custom framing company Framebridge LLC is now producing personal protective equipment — specifically a new face shield using acrylic it typically uses in its frames. The face shield includes a reusable halo worn above the ears and a removable shield made of nonporous polycarbonate. The face shields cost $4.50 a pop and the polycarbonate shield portions can be replaced for 80 cents apiece.

Orgenesis Inc. (ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced that it has entered into a collaboration agreement with the John Hopkins University (“JHU”) to utilize Orgenesis’ POCare platform to develop and supply a variety of cell and gene therapies and technologies, including cell-based immunotherapy technologies.

If you own shares in Orgenesis Inc. (NASDAQ:ORGS) then it's worth thinking about how it contributes to the volatility...

The timing and amount of any shares repurchased shall be subject to management’s discretion and will depend upon a variety of factors including general and business market conditions, corporate and regulatory requirements, share price, and alternative investment opportunities. Any share repurchases shall be in accordance with the Company’s repurchase plan under Rule 10b-18 under the Securities Exchange Act of 1934.

GERMANTOWN, Md., Jan. 13, 2020 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.

GERMANTOWN, Md., May 11, 2020 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering, global biotech company committed to accelerating commercialization.

GERMANTOWN, Md., Jan. 21, 2020 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a leading cell and gene therapy enabling company providing centralized CDMO.

GERMANTOWN, Md., May 22, 2020 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), a pioneering global biotech company committed to accelerating commercialization.

The acquisition included total stock and cash consideration of approximately $21 million, based on the value of the stock at closing. The first target for ranpirnase is human papillomavirus (HPV), the worldwide leading cause of genital warts.

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 3.) Acceleron Pharma Inc (NASDAQ: XLRN ) Aptose Biosciences ...

While we achieved strong company-wide revenue growth, more importantly, we generated $3.1 million in sales through our newly launched POCare platform. In 2019, we signed collaborations with several leading research and healthcare institutions.

Orgenesis Inc. (ORGS), a provider of point-of-care cell and gene therapy development, processing and treatment solutions (“POCare”), today announced the completion of the sale of its Masthercell Global, Inc. subsidiary, a contract development manufacturing organization (CDMO), to Catalent Pharma Solutions. Upon closing, Orgenesis received net proceeds of approximately $127 million from the transaction.

JV to utilize RevaTis’s patented technique to obtain mdMSCs through a minimally invasive muscle biopsy and leverage mdMSC manufacturing capability Plan to leverage Orgenesis’s.

GERMANTOWN, Md., Feb. 03, 2020 -- Orgenesis Inc. (NASDAQ: ORGS) (“Orgenesis” or the “Company”), today announced that Catalent Pharma Solutions has agreed to acquire Masthercell.

This past February, we completed the sale of Masthercell, which generated approximately $127 million in net proceeds to Orgenesis. This sale was an important step in our strategy to leverage our unique capabilities that directly address the key challenges facing the cell and gene therapy (CGT) industry. Despite the fact that CGT therapies have the potential to solve some of the most challenging diseases in the world, many of these therapies cost hundreds of thousands of dollars per patient, per year.

Exosomes, or extracellular vesicles (EVs), are small vesicles that transfer DNA, RNA, and proteins to other cells, thereby altering the function of the targeted cells. Exosomes are believed to provide the same therapeutic benefit of cells without the risks and difficulties of administering entire cells to patients. Together, Orgenesis and ExcellaBio have developed Bioxomes, which are synthetic exosomes/EVs.